Overview

Efficacy of N-Acetylcysteine in Improving/Normalizing ALT & AST in Patients of NAFLD

Status:
Not yet recruiting

Trial end date:
2023-05-15

Target enrollment:
0

Participant gender:
All

Summary

Currently researches are focusing on the effect of antioxidants in the treatment of non-alcoholic fatty liver disease (NAFLD). Since N-acetyl cysteine (NAC) has been proven to have antioxidant and anti-inflammatory properties, therefore, we will conduct this study to determine the effect of NAC in patients of NAFLD with raised liver enzymes.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Dow University of Health Sciences

Criteria

Inclusion Criteria:

- • Patients of both genders between the ages of 20 years and 60 years, giving consent
to be included in the study.

- Patients having fatty liver on ultrasound with raised ALT and AST levels

Exclusion Criteria:

- • Patients having other causes of steatosis eg, excessive alcohol consumption,

- Patients taking steatogenic medications such as, methotrexate , corticosteroids
etc.

- Patients suffering from other diseases that could increase ALT levels eg. Viral
hepatitis, HIV, autoimmune liver diseases, infiltrative liver diseases.

- Patients suffering from malignancies.

- Patients who are not compliant to the medicine.

- Pregnant and nursing females